|
1.
|
|
16 p, 1.2 MB |
A RAD51 assay feasible in routine tumor samples calls inhibitor response beyond BRCA mutation
/
Castroviejo-Bermejo, Marta (Vall d'Hebron Institut d'Oncologia) ;
Cruz Zambrano, Cristina (Universitat Autònoma de Barcelona) ;
Llop-Guevara, Alba (Vall d'Hebron Institut d'Oncologia) ;
Gutiérrez-Enríquez, Sara (Vall d'Hebron Institut d'Oncologia) ;
Ducy, Mandy (CHUL. Genomics Center) ;
Ibrahim, Yasir Hussein (Vall d'Hebron Institut d'Oncologia) ;
Gris-Oliver, Albert (Vall d'Hebron Institut d'Oncologia) ;
Pellegrino, Benedetta (University Hospital of Parma) ;
Bruna, Alejandra (University of Cambridge) ;
Guzmán, Marta (Vall d'Hebron Institut d'Oncologia) ;
Rodríguez, Olga (Vall d'Hebron Institut d'Oncologia) ;
Grueso, Judit (Vall d'Hebron Institut d'Oncologia) ;
Bonache, Sandra (Vall d'Hebron Institut d'Oncologia) ;
Moles-Fernández, Alejandro (Vall d'Hebron Institut d'Oncologia) ;
Villacampa Javierre, Guillermo (Vall d'Hebron Institut d'Oncologia) ;
Viaplana, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Gómez, Patricia (Vall d'Hebron Institut d'Oncologia) ;
Vidal, Marc (Vall d'Hebron Institut d'Oncologia) ;
Peg, Vicente (Instituto de Salud Carlos III) ;
Serres-Créixams, Xavier (Hospital Universitari Vall d'Hebron) ;
Dellaire, Graham (Dalhousie University) ;
Simard, Jacques (CHUL. Genomics Center) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Rubio, Isabel T. (Hospital Universitari Vall d'Hebron) ;
Dientsmann, Rodrigo (Vall d'Hebron Institut d'Oncologia) ;
Barrett, J. Carl (AstraZeneca) ;
Caldas, Carlos (Cancer Research UK (CRUK) Cambridge Cancer Centre) ;
Baselga Torres, Josep 1959-2021 (Memorial Sloan Kettering Cancer Center) ;
Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ;
Déas, Olivier (XenTech) ;
Jonkers, Jos (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ;
Masson, Jean-Yves (Laval University Cancer Research Center) ;
Cairo, Stefano (XenTech) ;
Judde, Jean-Gabriel (XenTech) ;
O'Connor, Mark J.. (AstraZeneca) ;
Diez, Orland (Vall d'Hebron Institut d'Oncologia) ;
Balmaña Gelpí, Judith (Vall d'Hebron Institut d'Oncologia) ;
Serra, Violeta (Instituto de Salud Carlos III) ;
Universitat Autònoma de Barcelona
Poly(-ribose) polymerase () inhibitors (i) are effective in cancers with defective homologous recombination repair (), including 1/2-related cancers. A test to identify additional -deficient tumors will help to extend their use in new indications. [...]
2018 -  10.15252/emmm.201809172
EMBO Molecular Medicine, Vol. 10 (october 2018)
|
|
|
2.
|
|
9 p, 2.5 MB |
Ultrasound-assisted exfoliation of a layered 2D coordination polymer with HER electrocatalytic activity
/
Contreras Pereda, Noemí (Institut Català de Nanociència i Nanotecnologia) ;
Moghzi, Faezeh (University of Tehran. School of Chemistry) ;
Baselga, Javier (Institut Català de Nanociència i Nanotecnologia) ;
Zhong, Haixia (Technische Universität Dresden. Faculty of Chemistry and Food Chemistry) ;
Janczak, Jan (Polish Academy of Science. Institute of Low Temperature and Structure Research) ;
Soleimannejad, Janet (University of Tehran. School of Chemistry) ;
Dong, Renhao (Technische Universität Dresden. Faculty of Chemistry and Food Chemistry) ;
Ruiz-Molina, Daniel (Institut Català de Nanociència i Nanotecnologia)
Large blue rectangular crystals of the 2D layered coordination polymer 1 have been obtained. The interest for this complex is two-fold. First, complex 1 is made of 2D layers packing along the (0-11) direction favored by the presence of lattice and coordinated water molecules. [...]
2021 - 10.1016/j.ultsonch.2020.105292
Ultrasonics sonochemistry, Vol. 70 (Jan. 2021) , art. 105292
|
|
|
3.
|
|
8 p, 473.7 KB |
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
/
Cruz, C. (Vall d'Hebron Institut d'Oncologia) ;
Castroviejo-Bermejo, Marta (Experimental Therapeutics Group) ;
Gutiérrez-Enríquez, Sara (Oncogenetics Group) ;
Llop-Guevara, A. (Experimental Therapeutics Group) ;
Ibrahim, Y. H. (Experimental Therapeutics Group) ;
Gris-Oliver, Albert. (Experimental Therapeutics Group) ;
Bonache, Sandra (Oncogenetics Group) ;
Morancho, Beatriz (Vall d'Hebron Institut d'Oncologia) ;
Bruna, Alejandra (Cancer Research UK Cambridge Institute. University of Cambridge) ;
Rueda, O. M. (Cancer Research UK Cambridge Institute. University of Cambridge) ;
Lai, Z. (AstraZeneca (USA)) ;
Polanska, U. M. (Cancer Research UK. Cambridge Institute) ;
Jones, G. N. (Cancer Research UK. Cambridge Institute) ;
Kristel, P. (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ;
de Bustos, L. (Experimental Therapeutics Group) ;
Guzmán, Marta (Experimental Therapeutics Group) ;
Rodríguez, O. (Experimental Therapeutics Group) ;
Grueso, Judit (Experimental Therapeutics Group) ;
Montalban, G. (Oncogenetics Group) ;
Caratù, Ginevra (Cancer Genomics Group) ;
Mancuso, Francesco M (Cancer Genomics Group) ;
Fasani, R. (Vall d'Hebron Institut d'Oncologia) ;
Jiménez, J. (Vall d'Hebron Institut d'Oncologia) ;
Howat, W. J. (Cancer Research UK. Cambridge Institute) ;
Dougherty, B. (AstraZeneca (USA)) ;
Vivancos, A. (Cancer Genomics Group) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Serres-Créixams, X. (Department of Radiology) ;
Rubio Rodríguez, Isabel Teresa (Hospital Universitari Vall d'Hebron) ;
Oaknin, Ana (Vall d'Hebron Institut d'Oncologia) ;
Cadogan, E. (Cancer Research UK. Cambridge Institute) ;
Barrett, J. Carl (AstraZeneca (USA)) ;
Caldas, Carlos (NIHR Cambridge Biomedical Research Centre (Regne Unit)) ;
Baselga Torres, Josep, 1959-2021, (Memorial Sloan Kettering Cancer Center) ;
Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ;
Arribas, Joaquín V. (Vicente) (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Jonkers, Jos (Cancer Genomics Group) ;
Diez, Orland (Hospital Universitari Vall d'Hebron) ;
O'Connor, M. J. (Oncology Innovative Medicine and Early Development Biotech Unit. AstraZeneca (UK)) ;
Balmaña Gelpí, Judith (Vall d'Hebron Institut d'Oncologia) ;
Serra, Violeta (Vall d'Hebron Institut d'Oncologia)
BRCA1 and BRCA2 (BRCA1/2) -deficient tumors display impaired homologous recombination repair (HRR) and enhanced sensitivity to DNA damaging agents or to poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi). [...]
2018 - 10.1093/annonc/mdy099
Annals of oncology, Vol. 29, Issue 5 (May 2018) , p. 1203-1210
|
|
|
4.
|
|
11 p, 542.8 KB |
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer
/
Reynolds, Kerry Lynn ;
Bedard, Philippe L (Toronto, ON Canada) ;
Lee, Se-Hoon (Seoul, Republic of Korea) ;
Lin, Chia-Chi (Taipei, Taiwan) ;
Tabernero, Josep (Hospital Universitari Vall d'Hebron) ;
Alsina, Maria (Hospital Universitari Vall d'Hebron) ;
Cohen, Ezra (La Jolla, CA USA) ;
Baselga Torres, Josep, 1959-2021, (New York, NY USA) ;
Blumenschein, George (Houston, TX USA) ;
Graham, Donna M. (Toronto, ON Canada) ;
Garrido-Laguna, Ignacio (Salt Lake City, UT USA) ;
Juric, Dejan (Fruit Street, Boston, MA 02114 USA) ;
Sharma, Sunil (Salt Lake City, UT USA) ;
Salgia, Ravi (Duarte, CA USA) ;
Seroutou, Abdelkader (Basel, Switzerland) ;
Tian, Xianbin (East Hanover, NJ USA) ;
Fernandez, Rose (East Hanover, NJ USA) ;
Morozov, Alex (New York, NY USA) ;
Sheng, Qing (Cambridge, MA USA) ;
Ramkumar, Thiruvamoor (East Hanover, NJ USA) ;
Zubel, Angela (Basel, Switzerland) ;
Bang, Yung-Jue (Seoul, Republic of Korea) ;
Universitat Autònoma de Barcelona
Human epidermal growth factor receptor 3 (HER3) is important in maintaining epidermal growth factor receptor-driven cancers and mediating resistance to targeted therapy. A phase I study of anti-HER3 monoclonal antibody LJM716 was conducted with the primary objective to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE), and dosing schedule. [...]
2017 - 10.1186/s12885-017-3641-6
BMC Cancer, Vol. 17 (september 2017)
|
|
|
5.
|
|
39 p, 4.7 MB |
mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer
/
Zabala-Letona, Amaia (Centro de Investigación Biomédica en Red de Cáncer) ;
Arruabarrena-Aristorena, Amaia (CIC bioGUNE) ;
Martín Martín, Natalia (Centro de Investigación Biomédica en Red de Cáncer) ;
Fernández Ruiz, Sonia (Centro de Investigación Biomédica en Red de Cáncer) ;
Sutherland, James D. (CIC bioGUNE) ;
Clasquin, Michelle (AGIOS Pharmaceuticals) ;
Tomás Cortázar, Julen (CIC bioGUNE) ;
Jiménez, José (Hospital Universitari Vall d'Hebron) ;
Torres Ramírez, Inés Ma. de (Hospital Universitari Vall d'Hebron) ;
Quang, Phong (AGIOS Pharmaceuticals) ;
Ximénez-Embún, Pilar (Centro Nacional de Investigaciones Oncológicas) ;
Bago, Ruzica (MRC Protein Phosphorylation and Ubiquitylation Unit) ;
Ugalde Olano, Aitziber (Hospital de Basurto (Bilbao, Biscaia)) ;
Loizaga Iriarte, Ana (Hospital de Basurto (Bilbao, Biscaia)) ;
Lacasa Viscasillas, Isabel (Hospital de Basurto (Bilbao, Biscaia)) ;
Unda, Miguel (Hospital de Basurto (Bilbao, Biscaia)) ;
Torrano, Verónica (Centro de Investigación Biomédica en Red de Cáncer) ;
Cabrera, Diana (CIC bioGUNE) ;
van Liempd, Sebastiaan M. (CIC bioGUNE) ;
Cendon, Ylenia (Universidad Autónoma de Madrid) ;
Castro, Elena (Centro Nacional de Investigaciones Oncológicas) ;
Murray, Stuart (AGIOS Pharmaceuticals) ;
Revandkar, Ajinkya (University of Lausanne) ;
Alimonti, Andrea (University of Lausanne) ;
Zhang, Yinan (Harvard School of Public Health) ;
Barnett, Amelia (AGIOS Pharmaceuticals) ;
Lein, Gina (AGIOS Pharmaceuticals) ;
Pirman, David (AGIOS Pharmaceuticals) ;
Cortazar, Ana Rosa (CIC bioGUNE) ;
Arreal, Leire (CIC bioGUNE) ;
Prudkin, Ludmila (Hospital Universitari Vall d'Hebron) ;
Astobiza, Ianire (CIC bioGUNE) ;
Valcárcel Jiménez, Lorea (CIC bioGUNE) ;
Zúñiga-García, Patricia (CIC bioGUNE) ;
Fernández Domínguez, Itziar (CIC bioGUNE) ;
Piva, Marco (CIC bioGUNE) ;
Caro-Maldonado, Alfredo (CIC bioGUNE) ;
Sánchez Mosquera, Pilar (CIC bioGUNE) ;
Castillo Martín, Mireia (Fundação Champalimaud) ;
Serra, Violeta (Hospital Universitari Vall d'Hebron) ;
Beraza, Naiara (CIC bioGUNE) ;
Gentilella, Antonio (Institut Català d'Oncologia) ;
Thomas, George (Institut Català d'Oncologia) ;
Azkargorta, Mikel (Carlos III Networked Proteomics Platform) ;
Elortza, Felix (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ;
Farràs, Rosa (Centro de Investigación Príncipe Felipe (València)) ;
Olmos, David (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Efeyan, Alejo (Centro Nacional de Investigaciones Oncológicas) ;
Anguita, Juan (Ikerbasque) ;
Muñoz, Javier (Carlos III Networked Proteomics Platform) ;
Falcón Pérez, Juan M. (Ikerbasque) ;
Barrio, Rosa (CIC bioGUNE) ;
Macarulla Mercadé, Teresa (Hospital Universitari Vall d'Hebron) ;
Mato, José M. (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ;
Martínez Chantar, Maria L. (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ;
Cordon Cardo, Carlos (Icahn School of Medicine at Mount Sinai) ;
Aransay, Ana M. (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ;
Marks, Kevin (AGIOS Pharmaceuticals) ;
Baselga Torres, Josep, 1959-2021, (Memorial Sloan Kettering Cancer Center) ;
Tabernero, Josep (Hospital Universitari Vall d'Hebron) ;
Nuciforo, Paolo (Hospital Universitari Vall d'Hebron) ;
Manning, Brendan D. (Harvard School of Public Health) ;
Marjon, Katya (AGIOS Pharmaceuticals) ;
Carracedo, Arkaitz (University of the Basque Country) ;
Universitat Autònoma de Barcelona
Activation of the PTEN-PI3K-mTORC1 pathway consolidates metabolic programs that sustain cancer cell growth and proliferation,. Here we show that mTORC1 regulates polyamine dynamics, a metabolic route that is essential for oncogenicity. [...]
2017 - 10.1038/nature22964
Nature, Vol. 547 (July 2017) , p. 109-113
|
|
|
6.
|
|
14 p, 1.9 MB |
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer
/
Rodón, Jordi (Hospital Universitari Vall d'Hebron) ;
Carducci, Michael (Johns Hopkins Kimmel Cancer Center) ;
Sepulveda-Sánchez, Juan M. (Hospital Universitario 12 de Octubre (Madrid)) ;
Azaro, Analía (Hospital Universitari Vall d'Hebron) ;
Calvo, Emiliano (Centro Integral Oncológico Clara Campal-HM CIOCC (Madrid, Espanya)) ;
Seoane Suárez, Joan (Hospital Universitari Vall d'Hebron) ;
Braña, Irene (Hospital Universitari Vall d'Hebron) ;
Sicart, Elisabet (Hospital Universitari Vall d'Hebron) ;
Gueorguieva, Ivelina (Eli Lilly and Company) ;
Cleverly, Ann (Eli Lilly and Company) ;
Pillay, N. Sokalingum (Eli Lilly and Company) ;
Desaiah, Durisala (Eli Lilly and Company) ;
Estrem, Shawn T. (Eli Lilly and Company) ;
Paz-Ares, Luis (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Holdhoff, Matthias (Johns Hopkins Kimmel Cancer Center) ;
Blakeley, Jaishri (Johns Hopkins University) ;
Lahn, Michael M.. (Eli Lilly and Company) ;
Baselga Torres, Josep, 1959-2021, (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
Purpose Transforming growth factor-beta (TGF-β) signaling plays a key role in epithelial-mesenchymal transition (EMT) of tumors, including malignant glioma. Small molecule inhibitors (SMI) blocking TGF-β signaling reverse EMT and arrest tumor progression. [...]
2014 - 10.1007/s10637-014-0192-4
Investigational New Drugs, Vol. 33 (december 2014) , p. 357-370
|
|
|
7.
|
|
347 p, 6.8 MB |
Evaluación del perfil hormonal en pacientes con cáncer de mama precoz sometidas a hormonoterapia adyuvante
/
Bellet Ezquerra, Meritxell ;
Cortés, Javier, dir. ;
Ruiz, Isabel, (Ruiz Camps) dir. ;
Baselga Torres, Josep, 1959-2021, dir. ;
Universitat Autònoma de Barcelona.
Departament de Medicina
La presente tesis se basa en el subestudio SOFT-EST, que se realizó en el marco de un ensayo clínico fase III adyuvante internacional para pacientes premenopáusicas con cáncer de mama (CM) precoz receptor hormonal positivo (estudio SOFT). [...]
[Barcelona] : Universitat Autònoma de Barcelona, 2016
|
|
|
8.
|
|
|
9.
|
|
96 p, 1.0 MB |
Aportación de los estudios farmacodinámicos en el desarrollo de tratamientos dirigidos contra dianas moleculares de cascadas de señalización proliferativas
/
Tabernero, Josep ;
Baselga Torres, Josep, 1959-2021, dir. (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Esta tesis doctoral se ha realizado por compendio de publicaciones de dos estudios fase I desarrollados en el servicio de Oncología del Hospital Vall d'Hebron, de la Universitat Autònoma de Barcelona, en Barcelona, España. [...]
This doctoral thesis has been written on the basis of two publications of two phase I studies developed at the Medical Oncology Department at the Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain. [...]
Bellaterra : Universitat Autònoma de Barcelona, 2013
|
|
|
10.
|
|
6 p, 263.8 KB |
A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer
/
Tan, E. H. (National Cancer Centre (Singapur). Department of Medical Oncology) ;
Ramlau, Rodryg (Regional Lung Disease Centre (Poznan). Department of Oncology) ;
Pluzanska, A. (Regional Oncology Centre (Lodz, Polònia). Oncological Chemotherapy Clinic) ;
Kuo, H. -P. (Chang Gung Memorial Hospital (Linkou, Taiwan). Department of Thoracic Medicine) ;
Reck, Martin (Hospital Grosshansdorf (Grosshansdorf, Alemanya). Department of Thoracic Oncology) ;
Milanowski, J. (Akademia Medyczna w Lublinie (Lublin, Polònia). Department of Pneumology, Oncology and Allergology) ;
Au, J. S. -K. (Queen Elizabeth Hospital (Hong Kong). Department of Clinical Oncology) ;
Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ;
Yang, P. -C. (National Taiwan University Hospital (Taipei, Taiwan)) ;
Damyanov, D. (Specialized Hospital for Active Treatment in Oncology (Sofia, Bulgaria)) ;
Orlov, S. (Pavlov State Medical University. Research Institute of Pulmonology (Sant Petersburg, Rússia)) ;
Akimov, Mikhail (Hoffmann-La Roche (Basel, Suïssa)) ;
Delmar, P. (Hoffmann-La Roche (Basel, Suïssa)) ;
Essioux, L. (Hoffmann-La Roche (Basel, Suïssa)) ;
Hillenbach, C. (Hoffmann-La Roche (Basel, Suïssa)) ;
Klughammer, B. (Hoffmann-La Roche (Basel, Suïssa)) ;
McLoughlin, P. (Hoffmann-La Roche (Basel, Suïssa)) ;
Baselga Torres, Josep, 1959-2021, (Hospital Universitari Vall d'Hebron)
Background: Identification of appropriate markers for predicting clinical benefit with erlotinib in non-small-cell lung cancer (NSCLC) may be able to guide patient selection for treatment. This open-label, multicentre, phase II trial aimed to identify genes with potential use as biomarkers for clinical benefit from erlotinib therapy. [...]
2010
Annals of oncology, Vol. 21, Issue 2 (2010) , p. 217-222
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
